Taysha Gene Therapies, Inc.
TSHABiotechnology
$4.22−0.24%As of Oct 29vs prior close
- Market cap
- $1.4B
- P/E (TTM)
- –
- From 52W high
- −39.54%
- EPS (LTM)
- -$0.42
- Revenue (LTM)
- $5.5M
- Net margin
- -2728.04%
- Dividend yield
- 0.00%
Nomior Score
30
Steady ProfileSpeculativeBottom 15% of the scored universe
Growth58
Quality34
Value38
Momentum43
Resilience22
Growth
+57.49%revenue a year over 3 fiscal years
YE22 $2.5MLTM $5.5M
Connections
Revenue to profitQ4 YE25
The operating loss was 516% of revenue, narrower by 470 pts on a year.
Who owns it
2funds, 1 tracked portfolio